NFL, Twitter Extend Partnership In Multi-Year Deal Involving Twitter Spaces
The National Football League announced Thursday it's extending its partnership with Twitter Inc (NYSE: TWTR) through a multi-year deal.
Why RBC Analysts Are Bullish On FactSet: What Investors Should Know
Strong demand and competitive positioning have turned RBC Capital Markets analysts Bullish on shares of FactSet Research Systems, Inc. (NYSE: FDS).
The RealReal Analyst: Luxury Marketplace Has Competitive Moat
Increased brand visibility, accelerating growth and a low EV/sales multiple have resulted in a Needham analyst’s bullish stance on the e-commerce platform The RealReal, Inc. (NASDAQ: REAL).
Why Wedbush Is Bullish On Brinker International
Wedbush Securities analysts expect post-COVID-19 growth to outpace pre-pandemic growth rates, resulting in bullish sentiment on shares of Brinker International, Inc. (NYSE: EAT).
4 Top Cloud Stock Picks For The Second Half Of 2021
Piper Sandler & Co. analyst Brent Bracelin released an industry note Wednesday, highlighting the firm’s top cloud application and analytics company stocks to own for the second half of 2021.
Why JPMorgan Is Raising Tesla Delivery Estimates, EPS Estimates, Price Target
JPMorgan analysts increased several estimates for Tesla, Inc. (NASDAQ: TSLA) Wednesday following the automaker’s second-quarter vehicle delivery update.
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.
What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company.
Why Credit Suisse Is Bullish On Boston Beer Company
A combination of reopenings and seltzer market growth has Credit Suisse bullish on Boston Beer Company, Inc (NYSE: SAM).
The Boston Beer Co. Analyst: Credit Suisse upgraded Boston Beer Co. from Neutral to Outperform and increased the price target from $1,304 to $1,490.
Arrowhead’s Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.
Takeaways On Unity Biotech’s Clinical Data From A Bull Analyst
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX).
The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target.